Susan Cheng, MD
Cardiovascular Disease · Los Angeles, CANPI 1154418291
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $54,525 of the $55,241 with a category attached, or 98.7%. 7 manufacturers reported payments, led by UCB Biosciences Inc. at 54.3% of the total. 2025 is the largest year on record at $34,275, more than ten times the $2,250 reported in 2020. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $4249.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB Biosciences Inc.$30K
- UCB, Inc.$18K
- Novartis$4K
- Zogenix Inc.$2K
- Viz.ai, Inc.$617
- Abbott$75
- plus $24 from 1 others
What the payments were for
- Consulting fees$54,52599%
- Food & beverage$7161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB Biosciences Inc. | 2 | $30,000 |
| UCB, Inc. | 5 | $18,000 |
| Novartis | 1 | $4,275 |
| Zogenix Inc. | 1 | $2,250 |
| Viz.ai, Inc. | 1 | $617 |
| Abbott | 2 | $75 |
| Vifor Pharma, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$47,550
- Viz.AI LVO$617
How this compares
$55,241 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.